8-K: Avanos Medical Reports Modest Revenue Growth, Adjusts Earnings Outlook for Q1 2025

Avanos Medical announces a slight increase in first quarter revenue, but lowers its adjusted diluted earnings per share guidance for 2025 due to tariff impacts.

Summary

• Avanos Medical, Inc. reported its first quarter 2025 financial results on May 6, 2025.
• Total net sales reached $167.5 million, a 0.8% increase compared to the same period last year.
• Net income was $6.6 million, a significant increase from the $0.5 million reported a year ago.
• Adjusted net income rose to $12.0 million from $10.1 million in the prior year.
• Diluted earnings per share increased to $0.14 from $0.01 year-over-year, while adjusted diluted earnings per share increased to $0.26 from $0.22.
• Adjusted EBITDA remained flat at $21.6 million compared to the previous year.
• The company is maintaining its 2025 revenue outlook between $665 million and $685 million.
• However, the adjusted diluted earnings per share guidance has been lowered to $0.75-$0.95, primarily due to the impact of recently announced tariffs.
• SNS segment net sales were $101.1 million, with 8.7% volume growth.
• PM&R segment net sales were $56.2 million, with radiofrequency ablation (RFA) products growing 8.2%.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue growth is modest and earnings are up, the lowered earnings guidance due to tariffs tempers enthusiasm. Management's positive comments provide some optimism.

Positives

• Net sales increased by 0.8% to $167.5 million.
• Net income improved significantly to $6.6 million from $0.5 million.
• Adjusted diluted earnings per share increased to $0.26 from $0.22.
• SNS segment showed strong performance with 8.7% volume growth.
• RFA products grew by 8.2% within the PM&R segment.
• Cash flow from operations improved to an inflow of $25.7 million.
• Free cash flow improved to an inflow of $19.0 million.
• Total debt outstanding decreased to $107.4 million from $134.7 million at the end of 2024.

Negatives

• Gross margin decreased to 53.6% from 57.1% last year.
• Adjusted gross margin decreased to 56.7% from 59.8% last year due to unfavorable pricing for hyaluronic acid (HA) products.
• The company lowered its adjusted diluted earnings per share guidance for 2025 to $0.75-$0.95 due to the impact of tariffs.
• Net sales in surgical pain and recovery for the first quarter of 2025 were 9.3% lower than last year.

Risks

• The company's future performance is subject to risks related to weakening economic conditions, pricing pressures, and supply chain disruptions.
• The ongoing regional conflicts between Russia and Ukraine and in the Middle East could impact the business.
• The company faces risks related to its ability to successfully execute its transformation initiative and manage divestiture, acquisition, or merger transactions.
• Inflationary pressures and changes in foreign exchange markets could adversely affect results.
• The impact of tariffs and the company's ability to mitigate them remains uncertain.
• Changes in reimbursement levels from third-party payors and a significant increase in product liability claims pose risks.
• The company is subject to investigative and legal proceedings and compliance risks.

Future Outlook

Avanos Medical is maintaining its 2025 revenue outlook between $665 million and $685 million but lowering its adjusted diluted earnings per share guidance to between $0.75 and $0.95, primarily due to the impact of recently announced tariffs.

Management Comments

• David Pacitti, Avanos's CEO, stated that transformation efforts have positioned the company well to accelerate growth.
• Pacitti expressed enthusiasm about the company's energy and strategic focus, which can be leveraged for consistent execution and margin enhancements.

Industry Context

Avanos Medical operates in the medical technology sector, focusing on solutions for nutrition, pain management, and recovery. The company's performance is influenced by factors such as healthcare spending, regulatory changes, and competition from other medical device manufacturers. The impact of tariffs on medical device components and finished goods is a growing concern for the industry.

Comparison to Industry Standards

• Comparing Avanos's 0.8% revenue growth to competitors like Medtronic or Johnson & Johnson, which often report growth in the low to mid-single digits, suggests a similar performance in a challenging market.
• However, companies like Stryker or Zimmer Biomet, which focus on specific high-growth areas, may show higher growth rates.
• Avanos's adjusted EBITDA margin of approximately 12.9% ($21.6 million/$167.5 million) is within the typical range for medical device companies, but could be improved through further cost management and operational efficiencies.
• Compared to companies like Boston Scientific or Abbott, which have diversified product portfolios and strong market positions, Avanos's reliance on specific segments like SNS and PM&R makes it more vulnerable to market fluctuations in those areas.

Stakeholder Impact

• Shareholders may react negatively to the lowered earnings guidance.
• Employees may be affected by cost containment measures implemented to mitigate the impact of tariffs.
• Customers may experience changes in pricing or product availability due to tariffs and supply chain adjustments.
• Suppliers may face pressure to reduce costs to help offset the impact of tariffs.
• Creditors should be aware of the potential impact of tariffs on the company's financial performance.

Next Steps

• Avanos Medical will host a conference call to discuss the results.
• Management will focus on mitigating the impact of tariffs through cost containment measures and leveraging international agreements.
• The company will continue to execute its transformation initiative and pursue growth opportunities in its key segments.

Key Dates

Keywords

Avanos Medical, financial results, first quarter 2025, net sales, earnings per share, EBITDA, tariffs, Specialty Nutrition Systems, Pain Management and Recovery, RFA, revenue guidance